Literature DB >> 54336

Vi antigen from Salmonella typhosa and immunity against typhoid fever. 11. Safety and antigenicity in humans.

D M Levin, K H Wong, H Y Reynolds, A Sutton, R S Northrup.   

Abstract

Safety and antigenicity of a purified preparation of Salmonella typhosa Vi antigen was evaluated in human volunteers. Dosages of Vi antigen at 25, 50, and 100 mug were less toxic than U.S. standard typhoid vaccine (lot 6A) containing 5 X 10(8) bacteria per dosage. Vi antigen in comparison with the standard typhoid vaccine induced higher hemagglutinating antibody but lower bactericidal antibody responses.

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 54336      PMCID： PMC415434          DOI： 10.1128/iai.12.6.1290-1294.1975

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  13 in total

1.  THE BACTERICIDAL ACTIONS OF O AND VI ANTIBODIES AGAINST SALMONELLA TYPHOSA.

Authors:  E OSAWA; L H MUSCHEL
Journal:  J Immunol       Date:  1964-02       Impact factor: 5.422

2.  THE PRESENT STATUS OF FIELD AND LABORATORY STUDIES OF TYPHOID AND PARATYPHOID VACCINES WITH SPECIAL REFERENCE TO STUDIES SPONSORED BY WORLD HEALTH ORGANIZATION.

Authors:  B CVJETANOVIC; K UEMURA
Journal:  Bull World Health Organ       Date:  1965       Impact factor: 9.408

3.  Immunological properties of Vi antigen isolated by chemical fractionation and by electrophoresis.

Authors:  M LANDY; R J TRAPANI; M E WEBSTER; F G JAVIS
Journal:  Tex Rep Biol Med       Date:  1963

4.  Studies on Vi antigen. VI. Immunization of human beings with purified Vi antigen.

Authors:  M LANDY
Journal:  Am J Hyg       Date:  1954-07

5.  Estimation of Vi antibody employing erythrocytes treated with purified Vi antigen.

Authors:  M LANDY; E LAMB
Journal:  Proc Soc Exp Biol Med       Date:  1953-04

6.  Enhancement of the immunogenicity of typhoid vaccine by retention of the V1 antigen.

Authors:  M LANDY
Journal:  Am J Hyg       Date:  1953-09

7.  Cellular inflammatory responses of man to bacterial endotoxin: a comparison with PPD and other bacterial antigens.

Authors:  S E Greisman; R B Hornick
Journal:  J Immunol       Date:  1972-12       Impact factor: 5.422

8.  Adhesion of Vi antigen and toxicity in typhoid vaccines inactivated by acetone or by heat and phenol.

Authors:  K H Wong; J C Feeley; M Pittman; M E Forlines
Journal:  J Infect Dis       Date:  1974-05       Impact factor: 5.226

9.  Vi antigen from Salmonella typhosa and immunity against typhoid fever. I. Isolation and immunologic properties in animals.

Authors:  K H Wong; J C Feeley; R S Northrup; M E Forlines
Journal:  Infect Immun       Date:  1974-02       Impact factor: 3.441

10.  Laboratory assays of different types of field trial typhoid vaccines and relationship to efficacy in man.

Authors:  M Pittman; H J Bohner
Journal:  J Bacteriol       Date:  1966-05       Impact factor: 3.490
View more
  7 in total

Review 1.  New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development.

Authors:  M M Levine; J B Kaper; R E Black; M L Clements
Journal:  Microbiol Rev       Date:  1983-12

2.  Purification and immunochemical properties of Escherichia coli B polysaccharide cross-reacting with Salmonella typhi Vi antigen: preliminary evidence for cross-reaction of the polysaccharide with Escherichia coli K1 antigen.

Authors:  B Szewczyk; A Taylor
Journal:  Infect Immun       Date:  1983-07       Impact factor: 3.441

3.  Salmonella choleraesuis and Salmonella typhimurium associated with liver cells after intravenous inoculation of rats are localized mainly in Kupffer cells and multiply intracellularly.

Authors:  N A Nnalue; A Shnyra; K Hultenby; A A Lindberg
Journal:  Infect Immun       Date:  1992-07       Impact factor: 3.441

4.  Comparative immunogenicities of Vi polysaccharide-protein conjugates composed of cholera toxin or its B subunit as a carrier bound to high- or lower-molecular-weight Vi.

Authors:  S C Szu; X R Li; R Schneerson; J H Vickers; D Bryla; J B Robbins
Journal:  Infect Immun       Date:  1989-12       Impact factor: 3.441

5.  Detection of urinary Vi antigen as a diagnostic test for typhoid fever.

Authors:  D N Taylor; J R Harris; T J Barrett; N T Hargrett; I Prentzel; C Valdivieso; C Palomino; M M Levine; P A Blake
Journal:  J Clin Microbiol       Date:  1983-10       Impact factor: 5.948

6.  Immune responses to Vi capsular polysaccharide typhoid vaccine in children 2 to 16 years old in Karachi, Pakistan, and Kolkata, India.

Authors:  R Leon Ochiai; M Imran Khan; Sajid B Soofi; Dipika Sur; Suman Kanungo; Young A You; M Atif Habib; Shah Muhammad Sahito; Byomkesh Manna; Shanta Dutta; Camilo J Acosta; Mohammad Ali; Sujit K Bhattacharya; Zulfiqar A Bhutta; John D Clemens
Journal:  Clin Vaccine Immunol       Date:  2014-03-05

Review 7.  Vaccines for preventing typhoid fever.

Authors:  Rachael Milligan; Mical Paul; Marty Richardson; Ami Neuberger
Journal:  Cochrane Database Syst Rev       Date:  2018-05-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.